ARS Pharmaceuticals Inc
SPRY
Get informed when a big investor buys or sells
+ FollowMarket Cap$611.71M
Close$
$-5.83
196.3% downside
Current Fair Value
196.3% downsideOvervalued by 196.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $611.71 Million |
|---|---|
| Enterprise Value | $587.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 0.88 |
| Outstanding Shares | 99,296,408 |
Return
| Return on Equity | -322.92% |
|---|---|
| Return on Assets | -68.84% |
| Return on Invested Capital | -83.06% |
Valuation & Multiples
| P/E Ratio | -3.06 |
|---|---|
| PEG | -3.9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.93 |
| Enterprise Value to EBIT | -2.97 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$31.33 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$31.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 29.03% |
|---|---|
| Total Calls | 48,000▼ 78.76% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.17%▼ 73.03% |
|---|---|
| Total Invested | $168.34M▼ 77.64% |
| Investors Holding | 72▼ 134.00% |
ESG Score
No data
About ARS Pharmaceuticals Inc
54 employeesSilverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...